LEVELS OF GENE EXPRESSION FOR LAD1 AND EGFR IN PATIENTS WITH LARYNGEAL CANCER

Venelin Marinov; Savina Hadjidekova

doi:10.35120/medisij040445v

Authors

Venelin Marinov University Hospital Sofiamed, Medical University of Sofia, Bulgaria Author
Savina Hadjidekova Department of Medical Genetics, Medical University of Sofia, Bulgaria Author

DOI:

https://doi.org/10.35120/medisij040445v

Keywords:

advanced laryngeal cancer, oncogenetics, LAD, laryngectomy, neck dissection, oncological surgery

Abstract

Laryngeal cancer is a multiheterogenic disease. Numerous genetic mechanisms are known to be involved in oncogenesis, disease progression, and patient survival prognosis. Some authors speculate that there is a genetic difference between the primary site and the secondary metastasis. We analyzed the known mutations associated with squamous cell cancers. We decided to evaluate gene expression levels of LAD1 and EGFR at three sites: the primary laryngeal site, the tumor periphery, and the lymph node suspected of metastatic spread. In this current study, we present patients operated on for advanced-stage laryngeal cancer. In every patient, a bilateral neck dissection has been performed as well as a total laryngectomy. The cohort consists of 20 patients. The tissues were fresh-frozen in liquid nitrogen, transported to the Genetics Department at Medical University Sofia, and evaluated by real-time PCR. Every tissue sample was pathologically evaluated. In the evaluated tissue samples, we identified gene expression differences between LAD1 and EGFR, even within samples from the same patient. 100 % of the patients are heavy smokers. 100% of the patients are male. We established a notable difference in EGFR and LAD1 gene expression. In some cases, even in different sites of the same patient. There may be prognostic value in LAD1 expression levels and in tumour progression and metastasis. Further studies are needed to establish and validate LAD1 as a predictive marker.

Downloads

Download data is not yet available.

References

Herbst, R. S. (2004). Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology, Biology, Physics, 59(2 Suppl.), S21–S26. https://doi.org/10.1016/j.ijrobp.2003.11.041 DOI: https://doi.org/10.1016/j.ijrobp.2003.11.041

Klobučar, M., Sedić, M., Gehrig, P., Grossmann, J., Bilić, M., Kovač Bilić, L., Pavelić, K., & Pavelić, S. (2016). Basement membrane protein ladinin-1 and the MIF-CD44-B1 integrin signaling axis are implicated in laryngeal cancer metastasis. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease, 1862(7), Article 1016. https://doi.org/10.1016/j.bbadis.2016.07.014 DOI: https://doi.org/10.1016/j.bbadis.2016.07.014

Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., Scott, W. J., Mumberg, D., & Ziegelbauer, K. (2013). BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Molecular cancer therapeutics, 12(11), 2319–2330. https://doi.org/10.1158/1535-7163.MCT-12-0993-T DOI: https://doi.org/10.1158/1535-7163.MCT-12-0993-T

Liu, H., Zhang, B., & Sun, Z. (2020). Spectrum of EGFR aberrations and potential clinical implications: Insights from integrative pan-cancer analysis. Cancer Communications, 40(1), 43–59. https://doi.org/10.1002/cac2.12005 DOI: https://doi.org/10.1002/cac2.12005

Marinov, V., Rangachev, J., Stancheva, G., Kaneva, R., Kisova, D. (2022). Changes in gene expression of EGFR and LAD1 in patients with metastatic squamous cell laryngeal carcinoma. International Bulletin of Otorhinolaryngology. https://journals.mu-varna.bg/index.php/orl/article/view/8596/7616 DOI: https://doi.org/10.14748/orl.v18i1.8596

Mongelluzzo, G. J., & Fourgas, E. C. (2024). Imaging for larynx cancer assessment. Operative Techniques in Otolaryngology–Head and Neck Surgery, 35(2), 141–148. https://doi.org/10.1016/j.otot.2024.04.004 DOI: https://doi.org/10.1016/j.otot.2024.04.004

Moon, B., et al. (2020). LAD1 expression is associated with the metastatic potential of colorectal cancer cells. BMC Cancer, 20(1), Article 1032. https://doi.org/10.1186/s12885-020-07660-0 DOI: https://doi.org/10.1186/s12885-020-07660-0

Nijkamp, M. M., Span, P. N., Terhaard, C. H., Doornaert, P. A., Langendijk, J. A., van den Ende, P. L., de Jong, M., van der Kogel, A. J., Bussink, J., & Kaanders, J. H. (2013). Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial. European journal of cancer (Oxford, England: 1990), 49(15), 3202–3209. https://doi.org/10.1016/j.ejca.2013.06.024 DOI: https://doi.org/10.1016/j.ejca.2013.06.024

Roskoski, R. (2014). The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research, 79, 34–74. https://doi.org/10.1016/j.phrs.2013.11.002 DOI: https://doi.org/10.1016/j.phrs.2013.11.002

Sigismund, S., Avanzato, D., & Lanzetti, L. (2018). Emerging functions of the EGFR in cancer. Molecular Oncology, 12(1), 3–20. https://doi.org/10.1002/1878-0261.12155 DOI: https://doi.org/10.1002/1878-0261.12155

Talaat, M. (1993). TNM staging of laryngeal cancer. Annals of Otology, Rhinology & Laryngology, 102(1 Pt 1), 7–8.